Acute kidney injury is a serious condition characterized by a sudden decline in kidney function, which can result from various causes, including trauma, infections, or medications. The condition accounts for around 10-15% of hospital admissions, with prevalence in intensive care unit (ICU) patients rising to over 50%. There is a high unmet clinical need for better therapies to treat acute kidney injury, as current options, such as dialysis, often fail to address the underlying causes effectively. Further, the growing focus on early detection, preventive measures, and novel treatments is likely to support pipeline growth in the coming years, offering hope for improved patient outcomes.
The Acute Kidney Injury Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into acute kidney injury therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute kidney injury. The acute kidney injury report assessment includes an analysis of over 100 pipeline drugs and 50+ companies. The acute kidney injury pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute kidney injury treatment guidelines to ensure optimal care practices.
The assessment section will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute kidney injury.
Acute kidney injury is a sudden loss of kidney function caused by reduced blood flow, direct kidney damage, or urinary obstruction. It often occurs due to severe infections, trauma, or nephrotoxic drugs. Acute kidney injury treatments include supportive care such as fluid management and electrolyte balancing. In severe cases, renal replacement therapy such as dialysis is used.
The acute kidney injury drug pipeline focuses on developing therapies targeting inflammation, oxidative stress, and cellular repair. These advancements aim to address the high unmet need for effective treatments, emphasizing early intervention and organ protection.
Acute kidney injury is a significant global health concern, affecting 14.7% to 31.5% of hospitalized patients. In the United States, its incidence has risen by 14% annually since 2001. The ISN 0by25 study reveals that 80% of acute kidney injury in low- and middle-income countries is community-acquired, with dehydration (46%) and hypotension (38%) as leading causes.
This section of the report covers the analysis of acute kidney injury drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total acute kidney injury clinical trials.
The drug molecule categories covered under the acute kidney injury pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for acute kidney injury.
The EMR acute kidney injury report insights include the profiles of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in acute kidney injury clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute kidney injury. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute kidney injury drug candidates.
The ARTEMIS study, sponsored by Alexion Pharmaceuticals, Inc., aims to evaluate the efficacy of a single dose of ravulizumab IV compared to a placebo in reducing the risk of AKI-related outcomes (MAKE) in chronic kidney disease patients undergoing non-emergent cardiac surgery with CPB. This Phase 3 trial, with an estimated 736 participants, is expected to conclude by February 2027.
The Phase II study, sponsored by Genentech, Inc., aims to evaluate the efficacy and safety of GDC-8264 in preventing cardiac surgery-associated acute kidney injury (AKI) and major adverse kidney events (MAKE90). With an estimated 404 participants, the study is set to begin on January 15, 2025, and is expected to conclude by November 15, 2027.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Acute Kidney Injury Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for acute kidney injury. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within acute kidney injury pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share